Shares of Emcure Pharmaceuticals soared close to 6 percent higher, coming at a kissing distance to its record high of Rs 1,580 on November 8 as investors cheered for the company's strong earnings ...

Pune-based Emcure is the 13th largest pharma company in India, with revenue of Rs 6,658 crore in FY24, of which 48.3% comes from the domestic market. Emcure’s IPO will open on July 3 and close ...

Mumbai/Pune: Emcure Pharmaceuticals Ltd. announces the launch of a public awareness campaign on stroke prevention with cricket legend, MS Dhoni. Under this initiative, Emcure and Dhoni ...

Emcure’s revenue growth was driven by a combination of strong performances in its international and domestic businesses. The company’s international business grew by 25 per cent y-o-y and 18 ...

Emcure Pharmaceuticals Limited was founded in 1983 and operates in Pune, India. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This ...

Emcure Pharmaceuticals Limited has announced the formation of a wholly-owned subsidiary, Emcutix Biopharmaceuticals Limited, which will focus exclusively on dermatology. To be spearheaded by ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Emcure Pharmaceuticals Ltd share price previously? Emcure Pharmaceuticals Ltd share price was up by 0.21% from the ...

Pune-based Emcure Pharmaceuticals Ltd has posted growth of 38.2 per cent in net profit at Rs. 201.55 crore during the quarter ended September 30, 2024, as compared to Rs. 145.84 crore during the same ...

Emcure Pharma is expected to announce its IPO share allotment status on Monday, July 8. The shares of Emcure Pharma were subscribed 67.87 times. The Emcure Pharma shares are expected to be listed ...

Emcure Pharmaceuticals Ltd. announces the launch of a public awareness campaign on stroke prevention with cricket legend, MS Dhoni. Under this initiative, Emcure and Dhoni, through a video urge ...

Emcure's revenue rose by 20.4 percent to Rs 2,002 crore in Q2 FY24, compared to Rs 1,663 crore in Q2 FY23, reflecting solid demand across its product portfolio. The growth was primarily driven by ...